You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Psoriatic arthritis
THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nash P, McInnes I, Mease P, et al
THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison
Annals of the Rheumatic Diseases 2016;75:353-354.